Efficacy and Safety of Sitafloxacin in Treating Low-risk Febrile Neutropenia in Patients with Lung Cancer
-
- On Rintaro
- Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan
-
- Matsumoto Takemasa
- Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan
-
- Ebi Noriyuki
- Department of Respiratory Oncology, Iizuka Hospital, Iizuka, Japan
-
- Doi Seiji
- Department of Respiratory Medicine, Japan Community Health Care Organization, Isahaya General Hospital, Isahaya, Japan
-
- Ishii Hiroshi
- Department of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino, Japan
-
- Furugen Makoto
- First Department of Internal Medicine, University of the Ryukyus Hospital, Nakagami, Japan
-
- Fujita Jiro
- First Department of Internal Medicine, University of the Ryukyus Hospital, Nakagami, Japan
-
- Ide Maako
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
-
- Kishimoto Junji
- Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan
-
- Okamoto Isamu
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
-
- Fujita Masaki
- Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan
この論文をさがす
説明
<p>Introduction: Febrile episodes in patients with cancer and chemotherapy-induced neutropenia can be life-threatening and generally require prompt administration of broad-spectrum antimicrobials. However, little evidence exists for treating patients with solid tumors and febrile neutropenia (FN) with oral antimicrobials.</p><p>Methods: In this prospective study, we aimed to determine the efficacy and safety of sitafloxacin (STFX) for treating FN in lung cancer patients. In this prospective study, low-risk FN patients with lung cancer received STFX. The primary endpoint was response rate, defined as 5 sequential days of absence of fever without adverse events. The study was registered as UMIN000010911.</p><p>Results: As a result, STFX was administered to 26 patients, all of whom survived during its administration. Of the 26, 14 completed primary endpoint (53.85%). The low response rate was attributed to occurrence of fevers of unknown cause rather than failure of FN treatment. Only two patients received antibacterial agents other than STFX. If response rate omitted absence of fever and been defined only as recovery from FN without changing microbial agents or serious complications, the response rate would have been 91.67%. Adverse events occurred in eight patients, none of which were serious.</p><p>Conclusions: In conclusion, STFX might be used to treat low-risk FN in patients with lung cancer; however, a more detailed study will be required in future.</p>
収録刊行物
-
- JMA Journal
-
JMA Journal 5 (3), 334-340, 2022-07-15
公益社団法人 日本医師会 / 日本医学会